Perrigo Pivots To 'Self Care' For 'Massive Opportunity' Beyond OTC Drugs
This article was originally published in The Rose Sheet
Executive Summary
Providing self-care products "opens this organization up to massive opportunity" which Perrigo will identify in early 2019, says new CEO Murray Kessler. It remains committed to selling or spinning off its Rx unit, though it's "just a few FDA approvals away from significantly" growing, he says as firm reports $68m net loss in its latest quarter.
You may also be interested in...
Subtracting Rx Adds To Perrigo OTC Pipeline
In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."
Perrigo Moves Closer To Exclusive Consumer Focus With UK Rx Generics Business Sale
Perrigo’s ambitions to become a consumer-focused company are a step closer after the firm announced an immediate sale of a ‘non-core’ asset.
Perrigo Returns To 'Model' For Success, Expects Surprises From 2020 Launches
Perrigo "walked away a little bit" from "a model that worked beautifully," says CEO Murray Kessler at investor conference, "In essence, all we've done over the last year is to put back in place the model that worked so well."